(Q39838100)

30 June 2019

title

PET of EGFR antibody distribution in head and neck squamous cell carcinoma models (English)

1 reference

30 June 2019

head and neck squamous cell carcinoma

main subject

0 references

1 reference

5

Xiaoyuan Chen

1 reference

30 June 2019

1

Gang Niu

1 reference

30 June 2019

4

Quynh-Thu Le

1 reference

30 June 2019

author name string

Zibo Li

series ordinal

2

1 reference

30 June 2019

Jin Xie

series ordinal

3

1 reference

30 June 2019

language of work or name

English

0 references

publication date

12 June 2009

1 reference

30 June 2019

The Journal of Nuclear Medicine

published in

1 reference

30 June 2019

volume

50

1 reference

30 June 2019

issue

7

1 reference

30 June 2019

page(s)

1116-1123

1 reference

30 June 2019

A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer

cites work

1 reference

12 December 2020

Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression.

1 reference

12 December 2020

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

1 reference

12 December 2020

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules

1 reference

12 December 2020

Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.

1 reference

12 December 2020

Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).

1 reference

12 December 2020

Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells

1 reference

12 December 2020

Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier

1 reference

12 December 2020

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

12 December 2020

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

12 December 2020

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

1 reference

12 December 2020

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

12 December 2020

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

1 reference

12 December 2020

Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action

1 reference

12 December 2020

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

1 reference

12 December 2020

In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.

1 reference

12 December 2020

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic

1 reference

12 December 2020

Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody

1 reference

12 December 2020

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

12 December 2020

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

1 reference

12 December 2020

Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.

1 reference

12 December 2020

Antibodies for molecular imaging of cancer

1 reference

12 December 2020

Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines

1 reference

12 December 2020

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

12 December 2020

Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck

1 reference

12 December 2020

A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.

1 reference

12 December 2020

Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors

1 reference

12 December 2020

Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody

1 reference

12 December 2020

Down regulation of epidermal growth factor receptors: direct demonstration of receptor degradation in human fibroblasts

1 reference

12 December 2020

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

12 December 2020

Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.

1 reference

12 December 2020

In vivo study of a technetium labelled anti-EGFr MoAB

1 reference

12 December 2020

Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line

1 reference

12 December 2020

10.2967/JNUMED.109.061820

Identifiers

DOI

1 reference

30 June 2019

PMC publication ID

6435376

1 reference

30 June 2019

PubMed publication ID

19525473

1 reference

30 June 2019